| 8000- | itraC, | The anti-cancer effects of itraconazole in epithelial ovarian cancer |
| - | NA, | Ovarian, | NA |
| 8001- | itraC, | Repurposing itraconazole as an anticancer agent |
| - | Review, | Var, | NA |
| 8013- | itraC, | High-dose itraconazole as a non-castrating therapy for a patient with biochemically-recurrent prostate cancer |
| - | Case Report, | Pca, | NA |
| 7986- | itraC, | Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma |
| - | Trial, | BCC, | NA |
| 8015- | itraC, | Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth |
| - | vitro+vivo, | BCC, | NA |
| 8016- | itraC, | Impact of combination chemotherapy with itraconazole on survival for patients with recurrent or persistent ovarian clear cell carcinoma |
| - | Human, | Ovarian, | NA |
| 8017- | itraC, | Itraconazole Inhibits Intracellular Cholesterol Trafficking and Decreases Phosphatidylserine Level in Cervical Cancer Cells |
| - | in-vitro, | Cerv, | CaSki |
| 8018- | itraC, | Chemo, | Impact of combination chemotherapy with itraconazole on survival of patients with refractory ovarian cancer |
| - | Trial, | Ovarian, | NA |
| 8019- | itraC, | Itraconazole Inhibits AKT/mTOR Signaling and Proliferation in Endometrial Cancer Cells |
| - | in-vitro, | Endo, | AN3CA | - | in-vitro, | Endo, | HEC-1A | - | in-vitro, | Endo, | HEC-50B | - | in-vitro, | Endo, | SNG-II |
| 8014- | itraC, | Itraconazole inhibits angiogenesis and tumor growth in non-small cell lung cancer |
| - | vitro+vivo, | NSCLC, | NA |
| 2180- | itraC, | Repurposing Drugs in Oncology (ReDO)—itraconazole as an anti-cancer agent |
| - | Review, | Var, | NA |
| 2179- | itraC, | Repurposing itraconazole for the treatment of cancer |
| - | Review, | Var, | NA |
| 2178- | itraC, | Itraconazole inhibits tumor growth via CEBPB-mediated glycolysis in colorectal cancer |
| - | in-vivo, | CRC, | HCT116 |
| 2177- | itraC, | Itraconazole improves survival outcomes in patients with colon cancer by inducing autophagic cell death and inhibiting transketolase expression |
| - | Study, | Colon, | NA | - | in-vitro, | CRC, | COLO205 | - | in-vitro, | CRC, | HCT116 |
| 8039- | IVM, | Ivermectin-Induced Apoptotic Cell Death in Human SH-SY5Y Cells Involves the Activation of Oxidative Stress and Mitochondrial Pathway and Akt/mTOR-Pathway-Mediated Autophagy |
| - | NA, | neuroblastoma, | SH-SY5Y |
| 8038- | IVM, | Ivermectin and gemcitabine combination treatment induces apoptosis of pancreatic cancer cells via mitochondrial dysfunction |
| - | in-vitro, | PC, | NA |
| 8037- | IVM, | Ivermectin inhibits tumor metastasis by regulating the Wnt/β-catenin/integrin β1/FAK signaling pathway |
| - | in-vitro, | Var, | NA |
| 8036- | IVM, | Ivermectin inhibits the growth of ESCC by activating the ATF4-mediated endoplasmic reticulum stress-autophagy pathway |
| - | in-vitro, | ESCC, | KYSE-30 |
| 8035- | IVM, | Ivermectin and non-parasitic disorders: An update |
| - | Review, | Var, | NA | - | Review, | AD, | NA | - | Review, | Stroke, | NA |
| 8034- | IVM, | doxoR, | Synergistic potential of Ivermectin and doxorubicin in oral squamous cell carcinoma: an in vitro investigation |
| - | in-vitro, | Oral, | NA |
| 8033- | IVM, | dietMet, | rMETase, | Direct comparison of efficacy of combining ivermectin versus five first-line chemotherapy drugs with recombinant methioninase against colon-cancer cells |
| - | in-vitro, | CRC, | HCT116 |
| 8032- | IVM, | Tumor growth suppression of ivermectin in gastric cancer cell lines and primary gastric cancer organoids |
| - | in-vitro, | GC, | SNU620 | - | in-vitro, | GC, | SNU719 |
| 8031- | IVM, | Antiparasitic agents in oncology: Innovative mechanisms, emerging evidence and clinical potential in cancer treatment |
| 8030- | IVM, | Metabolism and interactions of Ivermectin with human cytochrome P450 enzymes and drug transporters, possible adverse and toxic effects |
| - | Review, | Var, | NA |
| 8029- | IVM, | Ivermectin in Cancer Treatment: Should Healthcare Providers Caution or Explore Its Therapeutic Potential? |
| - | Review, | Var, | NA |
| 8028- | IVM, | Ivermectin as an Alternative Anticancer Agent: A Review of Its Chemical Properties and Therapeutic Potential |
| - | Review, | Var, | NA |
| 8027- | IVM, | Progress in Understanding the Molecular Mechanisms Underlying the Antitumour Effects of Ivermectin |
| - | Review, | Var, | NA |
| 8026- | IVM, | immuno, | Ivermectin converts cold tumors hot and synergizes with immune checkpoint blockade for treatment of breast cancer |
| - | vitro+vivo, | BC, | 4T1 |
| 8025- | IVM, | Ivermectin has New Application in Inhibiting Colorectal Cancer Cell Growth |
| - | in-vitro, | CRC, | SW480 | - | in-vivo, | CRC, | HCT116 |
| 8024- | IVM, | Ivermectin induces apoptosis of esophageal squamous cell carcinoma via mitochondrial pathway |
| - | vitro+vivo, | ESCC, | KYSE-30 | - | in-vitro, | ESCC, | NE3 |
| 8023- | IVM, | Antitumor effects of the antiparasitic agent ivermectin via inhibition of Yes-associated protein 1 expression in gastric cancer |
| - | vitro+vivo, | GC, | NA |
| 8022- | IVM, | Antibiotic ivermectin preferentially targets renal cancer through inducing mitochondrial dysfunction and oxidative damage |
| - | vitro+vivo, | RCC, | NA |
| 8021- | IVM, | The antiparasitic agent ivermectin induces chloride-dependent membrane hyperpolarization and cell death in leukemia cells |
| - | vitro+vivo, | AML, | HL-60 | - | NA, | lymphoma, | U937 | - | NA, | Pca, | DU145 |
| 8020- | IVM, | Ivermectin induces PAK1-mediated cytostatic autophagy in breast cancer |
| - | vitro+vivo, | BC, | NA |
| 8052- | IVM, | rMETase, | Selective Synergy of Ivermectin Combined With Recombinant Methioninase Against Colon-Cancer Cells in Contrast to Normal Fibroblasts |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | Nor, | Hs27 |
| - | in-vitro, | Lung, | A549 |
| 8050- | IVM, | doxoR, | Repurposing Ivermectin to augment chemotherapy's efficacy in osteosarcoma |
| - | in-vitro, | OS, | NA |
| 8049- | IVM, | Ivermectin Induces Cytostatic Autophagy by Blocking the PAK1/Akt Axis in Breast Cancer |
| - | vitro+vivo, | BC, | NA |
| 8048- | IVM, | Ivermectin as an inhibitor of cancer stem‑like cells |
| - | in-vitro, | BC, | MDA-MB-231 |
| 8047- | IVM, | The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug |
| - | Review, | Var, | NA |
| 8046- | IVM, | Antibiotic ivermectin selectively induces apoptosis in chronic myeloid leukemia through inducing mitochondrial dysfunction and oxidative stress |
| - | in-vitro, | CML, | NA |
| 8045- | IVM, | Ivermectin induces cell cycle arrest and apoptosis of HeLa cells via mitochondrial pathway |
| - | in-vitro, | Cerv, | HeLa |
| 8044- | IVM, | Current therapeutic applications and pharmacokinetic modulations of ivermectin |
| - | Review, | Var, | NA |
| 8043- | IVM, | Ivermectin suppresses tumour growth and metastasis through degradation of PAK1 in oesophageal squamous cell carcinoma |
| - | vitro+vivo, | ESCC, | KYSE-30 | - | in-vitro, | ESCC, | KYSE70 | - | in-vitro, | ESCC, | KYSE150 |
| 8040- | IVM, | Ivermectin, a potential anticancer drug derived from an antiparasitic drug |
| - | Review, | Var, | NA |
| 8041- | IVM, | Inhibition of Human Adenovirus Replication by the Importin α/β1 Nuclear Import Inhibitor Ivermectin |
| - | Review, | Nor, | NA |
| 8042- | IVM, | Antitumor effects of ivermectin at clinically feasible concentrations support its clinical development as a repositioned cancer drug |
| - | vitro+vivo, | Var, | NA |
| 1070- | IVM, | Ivermectin accelerates autophagic death of glioma cells by inhibiting glycolysis through blocking GLUT4 mediated JAK/STAT signaling pathway activation |
| - | vitro+vivo, | GBM, | NA |
| 1175- | IVM, | PDT, | Drug induced mitochondria dysfunction to enhance photodynamic therapy of hypoxic tumors |
| - | in-vitro, | Var, | NA |
| 1168- | IVM, | SRF, | Ivermectin synergizes sorafenib in hepatocellular carcinoma via targeting multiple oncogenic pathways |
| - | in-vitro, | HCC, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:% State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid